Immuno-Oncology Stocks Soar
Update: 2025-11-24
Description
Immuno-oncology industry thrives with precision medicine and AI, but faces challenges like drug pricing scrutiny and competition. Four key stocks reported impressive Q3 revenues, beating analyst expectations by an average of 27%. Exact Sciences, Incyte, and Natera led the pack with significant revenue growth and stock price increases.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
